Kura Oncology is committed to discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. We focus on the development of small molecule drug candidates that target cell signaling pathways that are important to driving the progression of certain cancers. We aim to employ molecular diagnostics to identify patients with cancers who are likely to benefit from our targeted drug candidates.
Ongoing Clinical Trials of Tipifarnib
|Phase 2 clinical trial of patients with solid tumors with HRAS mutations||Learn More »|
|Phase 2 clinical trial of patients with relapsed or refractory PTCL||Learn More »|
|Phase 2 clinical trial of patients with transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)||Learn More »|
|Phase 2 clinical trial of patients with Chronic Myelomonocytic Leukemia||Learn More »|
|Investigator-sponsored Phase 2 clinical trial of patients with urothelial carcinoma tumors, characterized by HRAS mutations||Learn More »|
Tipifarnib is an investigational drug candidate and has not yet been approved for use by regulatory authorities such as the U.S. Food and Drug Administration (FDA).